Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2023 Earnings Conference Call November 6, 2023 5:00 PM ET

Company Participants

Jamie Taylor - Head of Investor Relations

Dennis Lanfear - President, CEO and Chairman

Paul Reider - Chief Commercial Officer

Theresa LaVallee - Chief Development Officer

Rosh Dias - Chief Medical Officer

McDavid Stilwell - Chief Financial Officer

Conference Call Participants

Robyn Karnauskas - Truist Securities

Yigal Nochomovitz - Citigroup

Michael Nedelcovych - TD Cowen

Douglas Tsao - H.C. Wainwright

Christopher Schott - JPMorgan

Ash Verma - UBS

Operator

Good day and thank you for standing by. Welcome to the Coherus Biosciences Third Quarter 2023 Conference Call. At this time all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Jamie Taylor, Head of Investor Relations. Please go ahead.

Jamie Taylor

Good afternoon, everyone, and thank you for joining us. I am Jamie Taylor, Coherent's new Head of Investor Relations. I'm happy to be with you today. We issued a press release earlier today announcing our financial results for the third quarter of 2023. This release can be found on the Coherus BioSciences website and is also attached to the Form 8-K that we filed with the SEC today.

Today's call includes forward-looking statements regarding Coherus' current expectations about future events. These statements include, but are not limited to, our ability to gain approval for multiple new products and launch them, projections of expenses and revenue, projections of future market share or demand for any product, our expectations for market opportunity and the timing of our return to a cash flow positive.

All of these forward-looking statements involve substantial risks and uncertainties that are beyond our control and could cause actual results, performance or achievements to differ from those implied by the forward-looking statements. These statements are not guarantees of future performance and are subject to substantial risks and uncertainties that are discussed in our press release that we issued today as well as the documents that we file with the SEC. Forward-looking statements provided on the call today are made as of this date, and we undertake no duty to update or revise any forward-looking statements. Third quarter 2023 results are not necessarily indicative of results for future periods

With me on today's call are Denny Lanfear, CEO of Coherus; Dr. Theresa LaVallee, Chief Development Officer; Dr. Rosh Dias, Chief Medical Officer; Paul Reider, Chief Commercial Officer; and McDavid Stilwell, Chief Financial Officer.